Sanofi India Ltd vs Speciality Medicines Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3396 as of 06 May 15:30 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Speciality Medicines Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Speciality Medicines Ltd is ₹ 0 crore as of December 2023 . The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 .The Revenue of Speciality Medicines Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 .The EBITDA of Speciality Medicines Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 .The Net Profit of Speciality Medicines Ltd is ₹ 0 crore as of Jun '24 . The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 9 quarters. This represents a CAGR of -100.00% The dividend payout of Speciality Medicines Ltd changed from 0 % to 0 % over 9 quarters. This represents a CAGR of 0.0% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Speciality Medicines Ltd

Speciality Medicines Limited was originally incorporated as 'Speciality Medicines Private Limited' as a Private Limited Company, dated February 05, 2021, issued by the Registrar of Companies, Central Registration Centre.
Later on, the status was converted to Public Limited and the name of the Company was changed to 'Speciality Medicines Limited' and a fresh Certificate of Incorporation dated June 25, 2024 was issued to the Company by Registrar of Companies. The Company is engaged in marketing & distribution of finished formulations of Specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in Domestic as well as International Market.
The Company has presence over 35 countries. The Company deal in Specialty pharmaceuticals finished formulations Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet, Suspension and Tablet.

FAQs for the comparison of Sanofi India Ltd and Speciality Medicines Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Speciality Medicines Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Speciality Medicines Ltd is 277 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Speciality Medicines Ltd?

The stock performance of Sanofi India Ltd and Speciality Medicines Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Speciality Medicines Ltd?

As of May 6, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Speciality Medicines Ltd stock price is INR ₹316.2.

How do dividend payouts of Sanofi India Ltd and Speciality Medicines Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Speciality Medicines Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.